Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : WSJ BLOG/Health : Experimental Drug Might Open New Category of Sleep Aid

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 06:17pm CET

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Christopher Weaver

Patients with severe insomnia taking a Merck experimental sleep drug drifted off faster and slept longer than those taking placebos in two clinical studies discussed at a Boston sleep conference today.

The drug, suvorexant, opens a new category of sleep drugs by blocking orexin, the brain's chemical emissaries that promote alertness. Merck says it plans to apply for FDA approval later this year.

Both of Merck's trials included more than 1,000 patients with insomnia. Patients whose sleep troubles were caused by other medical problems weren't included in the studies. The results were reported after three months of taking the drug or a placebo.

Those taking suvorexant reported falling asleep 25.7 minutes faster than usual, and sleeping an hour longer in one trial. Merck's researchers also observed patients in sleep labs and determined that patients taking the drug fell asleep 36 minutes faster than usual, while those taking placebos fell asleep 26.6 minutes faster.

The second trial also showed the drug helped people sleep longer, though people in that group who took it didn't fall asleep faster than patients taking placebos.

The findings were presented at the Sleep 2012, an annual meeting of sleep scientists and health providers.

The U.S. market for sleep drugs sagged to $1.85 billion in 2011, down about 8% from the prior year, according to IMS Health, a health-care-information company. The decline was driven by generic competition for key sleep drugs.

Suvorexant could offer a new option for patients with chronic insomnia who routinely need sleeping pills, Merck hopes. Other sleep drugs on the market, such as Ambien, keep patients asleep for about two thirds of the night, while suvorexant provides longer rest, Dr. Darryle Schoepp, Merck's vice president in charge of neuroscience, said in an interview last week.

For decades, a series of sleep drugs have focused on "shutting down the whole brain in maybe a less natural way," Schoepp said. So-called Gaba agonists, such as Ambien, Sonata and Lunesta, which are often prescribed to be taken as needed, have been shown to have side effects, including sleep walking, in a small fraction of patients.

Merck says patients who routinely need sleep aids will better tolerate suvorexant, which also performed well in a cohort of patients Merck followed for a full year. In contrast to older drugs, Schoepp said, Merck's research showed that patients taking suvorexant experienced normal sleep rhythm.

The study showed suvorexant's main side effects were headaches and morning drowsiness.

 
 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
01/23 MERCK : Announces Second-Quarter 2018 Dividend
01/22 Global business group 'lit a flame' for long-term U.N. goals - chair
01/19 MERCK AND : These Two Biotechs Just Reported Key Data
01/19 EISAI : and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA®..
01/19 MERCK AND : First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patie..
01/19 MERCK AND : LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of..
01/19 MERCK AND : chalks up another win for Keytruda in lung cancer
01/18 MERCK AND : shares continue to rise after successful lung cancer trial
01/18 MERCK AND : The Consumer Health of Merck Walks the Talk with its WE100 Movement
01/17 MERCK AND : KEYTRUDA Significantly Improved Overall Survival and Progression-Fre..
More news
News from SeekingAlpha
01/23 Ionis Pharmaceuticals Is Poised To Disrupt Biotech
01/23 Merck declares $0.48 dividend
01/22 Merck Has Strong Conviction In KalVista's Phase 2 Clinical Trial Of KVD001 In..
01/21 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 20, 2018
01/20 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Battle, Acorda Takeover Speculation, O..
Financials ($)
Sales 2017 40 207 M
EBIT 2017 13 720 M
Net income 2017 5 361 M
Debt 2017 13 116 M
Yield 2017 3,06%
P/E ratio 2017 30,25
P/E ratio 2018 19,83
EV / Sales 2017 4,51x
EV / Sales 2018 4,39x
Capitalization 168 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 66,9 $
Spread / Average Target 8,4%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY8.53%168 278
JOHNSON & JOHNSON5.47%397 981
NOVARTIS1.29%226 840
PFIZER1.99%220 129
ROCHE HOLDING LTD.-4.34%211 542
AMGEN8.84%139 614